Bright Minds Biosciences (DRUG) Cash & Equivalents (2020 - 2026)
Bright Minds Biosciences (DRUG) posted Cash & Equivalents of $225.8 million for Q1 2026, up 253.66% on a QoQ basis from $63.9 million in Q4 2025, and up 481.97% year-over-year from $38.8 million in Q1 2025.
Bright Minds Biosciences (DRUG) Cash & Equivalents (2020 - 2026) Analysis & Trends
Bright Minds Biosciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $225.8 million for Q1 2026.
- Quarterly Cash & Equivalents rose 481.97% year-over-year to $225.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.8 million (up 481.97% YoY) and the FY2025 annual result came in at $60.2 million, up 1336.74% from the prior year.
- Cash & Equivalents was $225.8 million for Q1 2026 at Bright Minds Biosciences, up from $63.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $225.8 million in Q1 2026 and bottomed at $4.2 million in Q3 2024.
- A 5-year average of $31.6 million and a median of $8.3 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 62.14% — and 2025, when it surged 1336.74%.
- Bright Minds Biosciences' Cash & Equivalents stood at $8.3 million in 2022, then slumped by 39.87% to $5.0 million in 2023, then surged by 734.47% to $41.4 million in 2024, then surged by 54.07% to $63.9 million in 2025, then jumped by 253.66% to $225.8 million in 2026.
- Business Quant data shows DRUG's Cash & Equivalents at $225.8 million in Q1 2026, $63.9 million in Q4 2025, and $60.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Bright Minds Biosciences | 706.00 Mn | 706.00 Mn | - | 225.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 225.83 Mn |
| Dec 31, 2025 | 63.86 Mn |
| Sep 30, 2025 | 60.24 Mn |
| Jun 30, 2025 | 37.09 Mn |
| Mar 31, 2025 | 38.80 Mn |
| Dec 31, 2024 | 41.45 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 4.40 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 6.05 Mn |
| Mar 31, 2023 | 7.15 Mn |
| Dec 31, 2022 | 8.26 Mn |
| Sep 30, 2022 | 8.92 Mn |
| Jun 30, 2022 | 6.78 Mn |
| Mar 31, 2022 | 9.05 Mn |
| Dec 31, 2021 | 11.99 Mn |
| Sep 30, 2021 | 15.70 Mn |
| Jun 30, 2021 | 17.90 Mn |